This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2020 Sep;26(9):1276-1277.

doi: 10.1016/j.cmi.2020.05.006. Epub 2020 May 16.

Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19

S Gevers¹, M S G Kwa², E Wijnans², C van Nieuwkoop³

Affiliations

Affiliations

¹ Dutch Medicines Evaluation Board, Utrecht, the Netherlands. Electronic address: s.gevers@cbg-meb.nl.
² Dutch Medicines Evaluation Board, Utrecht, the Netherlands.
³ Dutch Medicines Evaluation Board, Utrecht, the Netherlands; Haga Teaching Hospital, Department of Internal Medicine, The Hague, the Netherlands.

PMID: 32422406
PMCID: PMC7228887
DOI: 10.1016/j.cmi.2020.05.006

Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19

S Gevers et al. Clin Microbiol Infect. 2020 Sep.

. 2020 Sep;26(9):1276-1277.

doi: 10.1016/j.cmi.2020.05.006. Epub 2020 May 16.

Authors

S Gevers¹, M S G Kwa², E Wijnans², C van Nieuwkoop³

Affiliations

¹ Dutch Medicines Evaluation Board, Utrecht, the Netherlands. Electronic address: s.gevers@cbg-meb.nl.
² Dutch Medicines Evaluation Board, Utrecht, the Netherlands.
³ Dutch Medicines Evaluation Board, Utrecht, the Netherlands; Haga Teaching Hospital, Department of Internal Medicine, The Hague, the Netherlands.

PMID: 32422406
PMCID: PMC7228887
DOI: 10.1016/j.cmi.2020.05.006

No abstract available

PubMed Disclaimer

Similar articles

Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Juurlink DN. Juurlink DN. CMAJ. 2020 Apr 27;192(17):E450-E453. doi: 10.1503/cmaj.200528. Epub 2020 Apr 8. CMAJ. 2020. PMID: 32269021 Free PMC article. Review. No abstract available.
Chloroquine and hydroxychloroquine in covid-19.
Ferner RE, Aronson JK. Ferner RE, et al. BMJ. 2020 Apr 8;369:m1432. doi: 10.1136/bmj.m1432. BMJ. 2020. PMID: 32269046 No abstract available.
COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.
White NJ, Watson JA, Hoglund RM, Chan XHS, Cheah PY, Tarning J. White NJ, et al. PLoS Med. 2020 Sep 3;17(9):e1003252. doi: 10.1371/journal.pmed.1003252. eCollection 2020 Sep. PLoS Med. 2020. PMID: 32881895 Free PMC article.
Of chloroquine and COVID-19.
Touret F, de Lamballerie X. Touret F, et al. Antiviral Res. 2020 May;177:104762. doi: 10.1016/j.antiviral.2020.104762. Epub 2020 Mar 5. Antiviral Res. 2020. PMID: 32147496 Free PMC article. Review.
COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?
Marmor MF. Marmor MF. Am J Ophthalmol. 2020 May;213:A3-A4. doi: 10.1016/j.ajo.2020.03.028. Epub 2020 Mar 25. Am J Ophthalmol. 2020. PMID: 32247518 Free PMC article. No abstract available.

See all similar articles

Cited by

Chloroquine against malaria, cancers and viral diseases.
Zhou W, Wang H, Yang Y, Chen ZS, Zou C, Zhang J. Zhou W, et al. Drug Discov Today. 2020 Sep 16;25(11):2012-22. doi: 10.1016/j.drudis.2020.09.010. Online ahead of print. Drug Discov Today. 2020. PMID: 32947043 Free PMC article. Review.
Potential interactions between antineoplastic agents and medicines used to treat Covid-19.
Sobreira da Silva MJ, Serpa Osorio-de-Castro CG, Paes RD, Negrete CL, Eugênio E, Moraes EL, Livinalli A. Sobreira da Silva MJ, et al. J Oncol Pharm Pract. 2022 Dec;28(8):1737-1748. doi: 10.1177/10781552211040494. Epub 2021 Oct 12. J Oncol Pharm Pract. 2022. PMID: 34637360 Free PMC article.
Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery.
Chen Y, Li MX, Lu GD, Shen HM, Zhou J. Chen Y, et al. Int J Biol Sci. 2021 Apr 10;17(6):1538-1546. doi: 10.7150/ijbs.59547. eCollection 2021. Int J Biol Sci. 2021. PMID: 33907517 Free PMC article. Review.
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.
Sharun K, Tiwari R, Yatoo MI, Natesan S, Megawati D, Singh KP, Michalak I, Dhama K. Sharun K, et al. Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8. Narra J. 2022. PMID: 38449903 Free PMC article. Review.
Hydroxychloroquine in COVID-19 Patients: Pros and Cons.
Younis NK, Zareef RO, Al Hassan SN, Bitar F, Eid AH, Arabi M. Younis NK, et al. Front Pharmacol. 2020 Nov 19;11:597985. doi: 10.3389/fphar.2020.597985. eCollection 2020. Front Pharmacol. 2020. PMID: 33364965 Free PMC article. Review.

See all "Cited by" articles

References

1. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. - PMC - PubMed
1. Goyal P., Choi J.J., Pinheiro L.C., Schenck E.J., Chen R., Jabri A. Clinical characteristics of Covid-19 in New York city. N Engl J Med. 2020 doi: 10.1056/NEJMc2010419. Online ahead of print. - DOI - PMC - PubMed
1. Plantone D., Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Invest. 2018;38:653–671. - PubMed
1. Taylor W.R., White N.J. Antimalarial drug toxicity: a review. Drug Saf. 2004;27:25–61. - PubMed
1. VigiAccessTM All data contained in VigiAccessTM is sourced from VigiBase®, the WHO's global database for ADRs. http://www.vigiaccess.org maintained by the Uppsala Monitoring Centre.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources